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Abstract: From September 2008, all UK schoolgirls aged 12−13 are being offered free
routine vaccination against the human papillomavirus, and girls aged 14−18 a limited catch−up
vaccination. The effectiveness of a national immunization programme depends on high uptake
rates and schoolgirls receiving all three doses. Two studies on parental attitudes and one
prospective cohort study on uptake of the first two doses have predicted uptake rates of about
70−80%. The aim of this study is to examine uptake rates of the first two doses of the actual
vaccine programme and parental attitudes. A questionnaire was distributed to three schools in
October and completed by school nurses. Data from two schools was used for analysis.
Results showed 91.1% of parents consented to the vaccine and uptakes rates were 95.3% for
both doses in school A and 85.6% and 85.2% for school B. Girls not being vaccinated on
schedule was a problem, but overall the results are encouraging. However ultimate success
depends on uptake of the third dose.
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Introduction
Cervical cancer is one of the most preventable
and curable of all cancers. However, with about
510,000 newly diagnosed cervical cancer cases and
288,000 deaths yearly, it is the second most common
cancer in women worldwide. Attempts to eradicate
cervical cancer began over 50 years ago with secon-
dary prevention in the form of the “Pap Smear” or
“Pap Test” and it is estimated that systematic cytol-
ogy−based screening can reduce deaths from cervical
cancer by around 70%.1 In the 1980s, the next major
breakthrough was made by zur Hausen, who discov-
ered a link between cervical cancer and HPV.2 Dur-
ing the following 20 years many epidemiological
studies were undertaken and at the beginning of the
1990 s, results clearly demonstrated that specific
“high−risk” types of HPV were carcinogenic and per-
sistent infection with these “high−risk” types was
necessary for the development of cervical cancer.3
Identification of a virus also implies that suc-
cessful prophylactic or therapeutic prevention should
prevent the disease(s) that it causes. Identification of
“high−risk” types of HPV led the way for the devel-
opment of vaccines against primary high risk HPV
infections and consequently against specific cancers,
and in particular cervical cancer. Large scale clinical
trials by two major pharmaceutical companies led to
the development of two safe and highly effective
prophylactic virus−like particle (VLP) vaccines, Gar-
dasil (Merck) and Cervarix (GlaxoSmithKline) .4,5,6
Both vaccines are effective against the 2 most com-
mon oncogenic types of HPV, HPV 16 and HPV 18,
responsible for about 70% of all cases of cervical
cancer. Furthermore, Gardasil also offers protection
again low−risk HPV 6 and HPV 11, responsible for
90% of all cases of genital warts. For maximum pro-
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tection, three doses of the vaccine need to be admin-
istered over a six month period before the recipient
becomes sexually active.
As of December 2008, HPV vaccines have been
licensed in 109 countries worldwide. A total of 20
countries: 2 in North America, 16 in Western Europe,
and 2 in Australasia have issued formal recommenda-
tions regarding their large scale use in national health
systems, immunization programs or public sector
health systems7,8 ( Table 1 ) . All these countries are
wealthy with well developed health systems and na-
tional immunization policies. All have moderate to
high population coverage in opportunistic or organ-
ized screening programs. This means the burden of
cervical cancer is relatively low compared to those
countries, especially third world countries, with poor
or no screening coverage. The recommended age of
vaccination varies from country to country. However,
with the exception of Austria, which also recom-
mends vaccinating males, the target population, in-
cluding limited “catch−up” programs, is females aged
between 9 and 26 years.7,8
While one Canadian study reported a first dose
uptake rate of 53%, there is little data on HPV vacci-
nation uptake in countries where the vaccination has
already been introduced.9 Several countries, including
the United Kingdom ( UK ) , have introduced free
school−based vaccination programmes. The effective-
ness of a national immunization programme depends
on high coverage.10 Two UK studies on parental atti-
tudes to the vaccination have predicted an uptake rate
of about 70−80% and one prospective cohort study
in Manchester, England, reported uptake rates of
70.6% and 68.5% for the first and second doses, re-
spectively.9,11,12 However 20% of parents did not re-
spond to the invitation to have their daughter vacci-
nated, and of the 8.1% of parents who refused to
have their daughters vaccinated, 23% did so not be-
cause they were against the vaccination per se, but
because it was a research study and not the actual
national vaccination programme.
The aim of this study is therefore to examine
uptake rates of the first two doses of the actual HPV
vaccine programme at two secondary schools in the
UK as well as parental attitudes to the vaccine.
North America
Routine
Vaccination
Catch−Up
Vaccination
Australasia
Routine
Vaccination
Catch−Up
Vaccination
USA 11−12 13−26 Australia 12−13 14−26
Canada 9−13 14−26 New Zealand 12−13 14−18
Western Europe
Routine
Vaccination
Catch−Up
Vaccination
Western Europe
Routine
Vaccination
Catch−Up
Vaccination
Austria 9−15 16−26 Lithuania Not stated −26
Belgium 10−13 14−26 Luxembourg 11−12 13−18
France 14 15−23 Netherlands 12 13−16
Denmark 12 13−15 Portugal 12 17
Germany 12−17 Dr. decides Spain 11−14 not stated
Greece 12−15 not stated Switzerland 11−14 15−19
Italy 12 none Sweden 13−17 none
Norway 11−12 13−16 UK 12−13 14−18
Table 1
Age Recommendations for HPV Vaccines7,8
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Materials and Methods
2.1 The UK National Vaccination Programme
In June 2006, after recommendations from the
Joint Committee on Vaccines and Immunisations
(JCVI), the Department of Health (DoH) announced
that a free, school − based vaccination programme
would be available on the National Health Service
(NHS) from September 2008. The DoH decided to
fund the vaccine for the following two cohorts:
1. An ongoing school−based vaccination (rou-
tine vaccination) for girls aged 12−13, gener-
ally administered in the second year of secon-
dary school (S2).
2. A predominantly school−based 2 year catch−
up vaccination programme for girls aged 13−
18.
In Scotland the catch−up programme will last
for 3 years starting in 2008, while in the rest of the
UK, the catch−up programme was to be for 2 years
starting in 2009. However, due to the savings the
government made on the “price−war” they invoked
between the two pharmaceutical companies manufac-
turing the vaccine, a catch−up vaccination of girls
aged 17−18 was also started in 2008 in other parts of
the UK.
Unlike Australia, a free catch−up programme for
women up to the age of 26 was not found to be cost
−effective, but the DoH did admit it may be benefi-
cial for some women and the issue is under review.
2.2. Participants
A total of 661 school girls, 330 in year S2 (12−
13yr) and 331 in years S5 and S6 (16−18yr) at three
secondary schools in central Scotland were included
in the study. However, only 411 school girls, 200 in
year S2 and 211 in years S5 and S6 were used in the
data analysis. To take part in the routine national
vaccination programme, girls in year S2 were ex-
pected, but not compelled, to obtain informed written
consent from their parents and to return the consent
form to the school nurse. Girls in years S5 and S6
taking part in the catch−up vaccination programme
did not require parental consent and could fill out the
consent form by themselves.
2.3 Schools
Three small to medium sized schools partici-
pated in the study. Since the three doses required for
the complete vaccination programme have not yet
been completed, information on uptake rates is re-
garded as “sensitive” and has not yet been released
to the public by the local health boards. Four schools
were contacted and the rectors of three schools in-
itially agreed to participate in the research. However,
the rector of school C was not given permission from
the local health board to release the data, so the re-
sults of two schools could only be included in the
analysis.
School A is a small school with a student role
of around 850. Almost 25% of student live outside
the catchment area and place a request to attend the
school. The academic level is high with around 50%
of students going on to 4 year public universities.
Both discipline problems and attendance problems
are few and parents take an active role in their
child’s education as well as the running of the
school. The number of students receiving free school
meals is 7.7%
School B is a medium sized school with a student
role of around 1250 students. Many of the students’
parents are unemployed so the students themselves
see no value in education. Around 40% leave school
as soon as it is legally possible at the age of 16. Dis-
cipline, truancy and in more recent years drug use
are also a problem. The number of students receiving
free school meals is 13.5%
Neither of the schools has a high rate of ethnic
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minority students. A factor that was significant in
vaccination refusal in the Manchester study.
2.4 Study procedure
A letter explaining the purpose of the study and
a questionnaire was sent to the rector of four schools
in Scotland in September 2008, one week before the
start of the national vaccination programme. Three
rectors agreed to their school taking part in the re-
search and stated that the questionnaire would be
filled out by the school nurse after the 2nd immuni-
zation had taken place in October. Follow−up tele-
phone calls took place if the data received was un-
clear or incomplete.
2.5 Ethics
Participation in the study was approved by senior
staff members of each school and anonymity was as-
sured. The school was free to refuse disclosing why
parents did not agree to have their daughter vacci-
nated.
Results
3.1 Compliance and Consent
While 20.3% of parent did not respond to the
invitation to have their daughters vaccinated in the
Manchester pilot study, no parents in school A and
only 8.6% of parents in school B did not respond.
The percentage of parents who refused to have their
daughter vaccinated was 8.1% in the Manchester
study, but 6.9% (n=5) and 2.3% (n=3) in schools A
and B, respectively. So compared to the overall pa-
rental consent of 71.6% in Manchester, 91.1% of
parents agreed to have their daughter vaccinated in
this study (Table2). With the exception of one parent
in school B stating her child had contra−indications
to the vaccine, no other parent stated a reason for re-
fusing to have his or her daughter vaccinated. There
was also no case where the parent refused consent,
but the child insisted on being vaccinated.
3.2 Uptake rates
While 2.1% of students who completed the first
dose in the Manchester study, did not go on to have
the second dose, all students in the routine vaccina-
tion of this study and all students in the catch−up
programme of School A completed both doses (Table
3). In school B, 0.8% (n=1) of the students in the
catch−up programme did not have the second vacci-
nation. However, the proportion of schoolgirls in
both age groups who were absent on the scheduled
vaccination day of the first dose in school A was sig-
nificantly higher than School B, 19.4% and 16% ,
compared to 5.3% and 5.5%, respectively. The ab-
sence rates of School A are similar to the Manchester
Manchester School A School B
12−13yr
(n=2817)
12−13yr
(n=72)
16−18yr
(n=77)
12−13yr
(n=128)
16−18yr
(n=134)
Response to invitation (%) 79.7 100 100 91.4 82.1
Parental Refusal of Vaccination (%) 8.1 6.9 NA 2.3 NA
Overall acceptance rate (%) 71.6 93.1 100 89.1 82.1
Uptake Rate for 1st Vaccination (%) 70.6 93.1 97.4 89.1 82.1
Uptake Rate for 2nd Vaccination (%) 68.5 93.1 97.4 89.1 81.3
Table 2
Number and proportion of schoolgirls receiving first two doses of the HPV vaccine
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study (16.3%). Regarding the second dose, the pro-
portion of girls who failed to have the vaccination on
time in School B doubled, however the absence rate
in the Manchester study was still twice that of
School B.
3.3 Catch−Up Vaccination
In the catch−up vaccination, 17.9% of girls in
the catch−up programme of school B did not return
the consent form, compared to 0% of girls in school
A. However, while all girls consented to the vaccine
in School A, two girls were absent on both the
scheduled and re−scheduled vaccine days for both
doses, resulting in failure to be vaccinated.
Discussion
Several studies have shown that an uptake rate
of 66% is necessary to significantly reduce rates of
cervical cancer and when vaccinating girls alone an
uptake rate of at least 80% has to be obtained to get
the same results as vaccinating both sexes.13 This was
achieved in this study. For the vaccine to be effective
girls have to receive all three doses. Health officials
have expressed fears that girls may not continue to
have all three vaccinations, and thus reduce the effec-
tiveness of the vaccine. In this study, all students in
the routine vaccination who gave consent received
both doses and only one student in the catch−up pro-
gramme failed to have the second dose. Since she
was in the catch−up group it is possible she may
have left school between the first and second dose
and would need to continue the programme with her
GP.
While compliance with both doses was high,
compliance with the vaccine schedule was not. If we
look at the proportion of girls vaccinated on time, we
can see that in School A which has an unauthorized
absence rate of just 3.3%, almost 20% of the girls in
the routine vaccination programme were absent on
the scheduled day of the first dose. In the catch−up
programme at school A, while the consent rate was
100%, only 97.4% of girls received the first and sec-
ond dose. This was because 2 girls were absent an
all 4 set days for the vaccinations. This means that
students who were studying for university entrance
exams missed 4 days of classes presumably because
they were afraid of having an injection. Research
conducted in the UK one year before the national
vaccination programme commenced regarding atti-
Manchester School A School B
12−13yr 12−13yr 16−18yr 12−13yr 16−18yr
Received first dose (%) 70.6 93.1 97.4 89.1 82.1
On schedule 59.1 85.0 81.8 84.4 77.6
Later 11.5 18.1 15.6 4.7 4.5
Absence rate for scheduled 1st dose (%) 16.3 19.4 16 5.3 5.5
Received second dose (%) 68.5 93.1 97.4 89.1 81.3
On schedule 52.3 93.1 97.4 77.4 71.6
Later 16.2 0 0 11.7 9.7
Missed second dose 2.1 0 0 0 0.8
Absence rate for scheduled 2nd dose (%) 25.9 0 0 13.1 12.8
Table 3
Proportion of schoolgirls who were vaccinated on schedule and absentee rates
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tudes to the HPV vaccination showed that the main
concern of girls having the vaccination was fear of
pain.14 Influenza vaccination is not common in the
UK, so most children have no routine vaccinations
after the age of 5.15 The results of this study suggest
that more effort needs to be taken to reassure those
girls who are afraid of having the vaccine. Further-
more, since the third vaccine dose is schedule for
March one month before the beginning of university
entrance exams, re−scheduling a make−up day for
those girls who missed the vaccination may be diffi-
cult since girl do not attend school from April and
they may be more concerned with studying for their
exams than completing the vaccination schedule.
In school B, 17.9% of girls did not return their
consent form. This may be due to the fact that after
the age of 16 students are not required by law to at-
tend school and absences are common. Many stu-
dents leave school during the academic year, so it
will be essential that girls who do not attend school
regularly are identified and those who do not receive
all or some of their vaccinations at school get the
proper follow−up with their GP.
Conclusion
In this study 91.1% of parents consented to hav-
ing their daughter vaccinated against HPV. This is
consistent with other routine childhood vaccination
rates in the UK. The fear of HPV vaccination induc-
ing early onset of sexual activity or vaccination
safety do not seem to be not an issue. Similarly the
problem of a parent refusing consent but her daugh-
ter wanting to be vaccinated did not arise.
Uptake rates for both the first and the second
vaccines were high and with the exception of one
student all students who had the first vaccination also
underwent the second one. However to achieve this
schools had to set a make−up day for a significant
number of students who were absent of the sched-
uled day and this may be disruptive to both the
school calendar and the girls’ studies, especially in
the older age group of the catch − up vaccination.
More time needs to be spent with girls who fear in-
jections.
The results of this study are encouraging for the
success of the UK national vaccination programme to
eradicate cervical cancer. However, the ultimate suc-
cess depends on the uptake rates of the third dose,
scheduled to be given in March 2009.
Study Limitations
This study examined uptake rates at two schools
in Scotland, neither of which were large inner−city
schools where the number of ethnic minority students
and those receiving free school meals tend to be
higher. Both of these factors were quoted as being
significant with regards to low−up take rates in the
Manchester study.
Acknowledgments
The author is deeply grateful to the three
schools who agreed to participate in the study and to
the school nurses who took the time to fill out the
questionnaire.
References
1. Parkin D, Bray F. Chapter 2: The burden of HPV−
related cancers. Vaccine 2006; 24 Suppl 3: S3
/11−25.
2. zur Hausen H. Viruses in human cancers. Science
1991 ; 254(5035) : 1167−73.
3. Bosch F, Bernaola Iturbe E. [The human papillo-
mavirus vaccine and the incorporation of pe-
diatrics in cervical cancer prevention]. An Pe-
diatr(Barc) 2006 ; 65(5) : 411−3.
4. Paavonen J, Jenkins D, Bosch F, Naud P, Salm-
erón J, Wheeler C, et al. Efficacy of a pro-
phylactic adjuvanted bivalent L1virus−like−
particle vaccine against infection with human
papillomavirus types 16 and 18 in young
? ??????? ??? ?????
????
???????????????????????????????????????????????????????????????????????????????
women: an interim analysis of a phase III
double − blind, randomised controlled trial.
Lancet 2007; 369(9580): 2161−70.
5. Joura E, Leodolter S, Hernandez − Avila M,
Wheeler C, Perez G, Koutsky L, et al. Effi-
cacy of a quadrivalent prophylactic human
papillomavirus(types 6, 11, 16, and 18) L1 vi-
rus−like−particle vaccine against high−grade
vulval and vaginal lesions: a combined analy-
sis of three randomised clinical trials. Lancet
2007 ; 369(9574) : 1693−702.
6. Quadrivalent vaccine against human papillomavi-
rus to prevent high−grade cervical lesions. N
Engl J Med 2007 ; 356(19) : 1915−27.
7. Koulova A, Tsui J, Irwin K, Van Damme P, Biel-
lik R, Aguado M. Country recommendations
on the inclusion of HPV vaccines in national
immunization programmes among high − in-
come countries, June 2006 − January 2008.
Vaccine 2008.
8. TC W. Current Status of HPV Vaccination Rec-
ommendations. HPV Today 2008(14) : 8−9.
9. Brabin L, Roberts SA, Stretch R, Baxter D, Cham-
bers G, Kitchener H, et al. Uptake of first two
doses of human papillomavirus vaccine by
adolescent schoolgirls in Manchester : pro-
spective cohort study. British Medical Journal
2008 ; 336(7652) : 1056−58.
10. Raffle A. Challenges of implementing human pa-
pillomavirus (HPV) vaccination policy. BMJ
2007 ; 335(7616) : 375−7.
11. Waller J, Marlow L, Wardle J. Mothers’ attitudes
towards preventing cervical cancer through
human papillomavirus vaccination : a qualita-
tive study. Cancer Epidemiol Biomarkers
Prev 2006 ; 15(7) : 1257−61.
12. Brabin L, Roberts S, Farzaneh F, Kitchener H.
Future acceptance of adolescent human papil-
lomavirus vaccination : a survey of parental
attitudes. Vaccine 2006 ; 24(16) : 3087−94.
13. Hughes J, Garnett G, Koutsky L. The theoretical
population−level impact of a prophylactic hu-
man papilloma virus vaccine. Epidemiology
2002 ; 13(6) : 631−9.
14. Shucksmith J, Philip K, Spratt J, McNaughton R.
Knowledge of HPV and attitudes towards
HPV immunisation amongst young people,
parents, educators and health professionals.
NHS Health Scotland 2008.
15. Immunisation NHS. Available at http : //www.im-
munisation. nhs. uk/Vaccines Accessed Janu-
ary 20th 2009.
????????? ?????
????
???????????????????????????????????????????????????????????????????????????????
